WHO was notified by Ministry of Health & Sport, Myanmar, on 24th July 2017 of 13 cases of Influenza A(H1N1)pdm09. According to MoHS data as at 15 October 2017, there were 1,198 cases of severe acute respiratory infection and 401 cases are laboratory confirmed Influenza A(H1N1) pdm09. Among deaths with influenza, 38 deaths were likely due to Influenza whereas 22 were likely due to Influenza with co-morbidities. Majority of laboratory confirmed cases and deaths were from Yangon, Ayeyarwady and Bago Regions.
Greater Mekong Sub-region (GMS) countries are dramatically reducing the burden of malaria. At the same time, success may be threatened by antimalarial drug resistance. Malaria Policy Advisory Committee constituted by WHO recommended eliminating malaria. The 10th East Asia Summit (EAS) in 2015 endorsed the Malaria Elimination Roadmap to address the challenges in malaria elimination. Ministry of Health and Sports of Myanmar with the support of Asia Pacific Leaders Malaria Alliance (APLMA), WHO and UNOPS are preparing for a high level ‘Malaria Week’, from 4 – 8 December 2017 in Nay Pyi Taw.
Japanese Encephalitis (JE) is an important public health problem in South East Asia and the Pacific. In Myanmar, the national Expanded Programme on Immunization (EPI) with the support of WHO and UNICEF is introducing JE vaccine routinely from 2018. Prior to this, a nationwide catch-up vaccination campaign is targeting 14 million children (9 months to 15 years) during November and December 2017 with the support of GAVI funds. This approach is expected to provide high immunity against JE before incorporation of JE vaccines into the national routine immunization schedule. Both campaign and routine programmes will use WHO prequalified (SA 14-14-2) JE vaccine...
Viral Hepatitis is a major cause of liver cancer and cirrhosis, contributing to premature morbidity and mortality, and undermining economic growth and the push to achieve health and wellbeing for all. In Myanmar, National Hepatitis Control Programme was established in late 2014 with the strong collaborative effort of MoHS, WHO, Liver foundation, local NGOs and INGOs. Viral hepatitis prevention and control activities are strengthened in Myanmar since 2014. Furthermore, hepatitis C treatment with oral, direct acting antivirals is being pioneered, since June 2017, in designated hospitals at Yangon, Mandalay and Nay Pyi Taw.